Impact of drug-eluting stents with different coating strategies on stent thrombosis: A meta-analysis of 19 randomized trials

Cardiology Journal

Volumn 21, Issue 5, 2014, Pages 557-568

  Niu, Xiaowei ^a   Yang, Cuiling ^b   Chen, De ^a   He, Shengliang ^a   Yan, Dong ^a   Yao, Yali ^a  

^a LANZHOU UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Biodegradable polymers; Drug eluting stents; Meta analysis; Permanent polymers; Stent thrombosis

Indexed keywords

ARTICLE; BIODEGRADABLE POLYMER DRUG ELUTING STENT; BIOLIMUS ELUTING STENT; CARDIOVASCULAR MORTALITY; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; HEART INFARCTION; HUMAN; INCIDENCE; META ANALYSIS; PACLITAXEL ELUTING STENT; PERMANENT POLYMER DRUG ELUTING STENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SIROLIMUS ELUTING STENT; STENT THROMBOSIS; TREATMENT OUTCOME; CORONARY RESTENOSIS; MYOCARDIAL INFARCTION; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

BIOMATERIAL;

COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; GUIDELINE ADHERENCE; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84908291448     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.a2014.0002     Document Type: Article

References (51)

1. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med, 2013; 368: 254–265.
2. Kirtane AJ, Gupta A, Iyengar S et al. Safety and efficacy of drug- eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation, 2009; 119: 3198–3206
3. Kastrati A, Mehilli J, Pache J et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 2007; 356: 1030–1039
4. Kimura T, Morimoto T, Nakagawa Y et al. Very late stent thrombosis and late target lesion revascularization after sirolimus- eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation, 2012; 125: 584–591
5. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol, 2006; 48: 193–202
6. Luscher TF, Steffel J, Eberli FR et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation, 2007; 115: 1051–1058
7. Byrne RA, Joner M, Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol, 2009; 57: 567–584
8. Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol, 2007; 27: 1500–1510
9. Jukema JW, Ahmed TA, Verschuren JJ, Quax PH. Restenosis after PCI. Part 2: Prevention and therapy. Nat Rev Cardiol, 2012; 9: 79–90
10. Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet, 2012; 379: 1393–1402
11. Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. J Am Coll Cardiol Cardiovasc Imaging, 2009; 2: 625–628
12. Kandzari DE, Leon MB, Popma JJ et al. Comparison of zotarolimus- eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol, 2006; 48: 2440–2447
13. Byrne RA, Kastrati A. No country for old stents? Improving long- term patient outcomes with biodegradable polymer drug-eluting stents. Expert Rev Cardiovasc Ther, 2012; 10: 429–432
14. Hamilos MI, Ostojic M, Beleslin B et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol, 2008; 51: 2123–2129
15. Stefanini GG, Kalesan B, Serruys PW et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet, 2011; 378: 1940–1948
16. Koppara T, Joner M, Bayer G et al. Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation. Thromb Haemost, 2012; 107: 1161–1171
17. Byrne RA, Kastrati A, Massberg S et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol, 2011; 58: 1325–1331
18. Barlis P, Regar E, Serruys PW et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: A LEADERS trial sub-study. Eur Heart J, 2010; 31: 165–176
19. Christiansen EH, Jensen LO, Thayssen P et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer- coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): A randomised non-inferiority trial. Lancet, 2013; 381: 661–669
20. Kastrati A, Neumann FJ. SORT OUT V: A new episode in the DES wars. Lancet, 2013; 381: 609–611
21. Higgins JPT, Green S. Cochrane handbook for systematic reviews of Interventions Version 5.1, 0. Updated March 2011. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org.
22. Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation, 2007; 115: 2344–2351
23. Cassese S, Ndrepepa G, King LA et al. Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison. Heart, 2012; 98: 1632–1640
24. Mehilli J, Byrne RA, Wieczorek A et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J, 2008; 29: 1975–1982
25. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet, 2008; 372: 1163–1173
26. Byrne RA, Kastrati A, Kufner S et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: The Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J, 2009; 30: 2441–2449
27. Li Q, Wang LF, Yang XC et al. Efficacy comparison of primary percutaneous coronary intervention with biodegradable polymer- and durable polymer-based sirolimus-eluting stents for patients with acute myocardial infarction. Zhonghua xin xue guan bing za zhi, 2010; 38: 886–890
28. Kadota K, Muramatsu T, Iwabuchi M et al. Randomized comparison of the Nobori Biolimus A9-eluting stent with the sirolimus- eluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv, 2012; 80: 789–796
29. Meredith IT, Verheye S, Dubois CL et al. Primary endpoint results of the EVOLVE trial: A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol, 2012; 59: 1362–1370
30. Separham A, Sohrabi B, Aslanabadir N et al. The twelve-month outcome of biolimus eluting stent with biodegradable polymer compared with an everolimus eluting stent with durable polymer. J Cardiovasc Thoracic Res, 2011; 3: 113–116
31. Xu B, Dou K, Yang Y, et al. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus- eluting stent in the treatment of patients with de novo native coronary artery lesions: The NOYA I trial. EuroIntervention, 2012; 8: 796–802
32. Smits PC, Hofma S, Togni M et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus- eluting stent (COMPARE II): A randomised, controlled, non-inferiority trial. Lancet, 2013; 381: 651–660
33. Zhang Y, Shen J, Li Z et al. Two-year clinical outcomes of different drug-eluting stents with different polymer coating strategies in coronary artery heart disease: A multi-centre, randomised, controlled clinical trial. Int J Cardiol, 2013; 168: 2646–2652
34. Chevalier B, Serruys PW, Silber S et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The Nobori 1 trial. EuroIntervention, 2007; 2: 426–434
35. Krucoff MW, Kereiakes DJ, Petersen JL et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: Primary results of the COSTAR (Cobalt Chromium Stent With Antiprolife- rative for Restenosis) II study. J Am Coll Cardiol, 2008; 51: 1543–1552
36. Chevalier B, Silber S, Park SJ et al. Randomized comparison of the nobori biolimus A9- eluting coronary stent with the taxus liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The NOBORI 1 trial-phase 2. Circ Cardiovasc Interv, 2009; 2: 188–195
37. Ormiston JA, Abizaid A, Spertus J et al. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: A randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberte paclitaxel-eluting stent in de novo native coronary artery lesions. Circ Cardiovasc Interv, 2010; 3: 556–564
38. Natsuaki M, Kozuma K, Morimoto T et al. Biodegradable Polymer Biolimus-eluting Stent versus Durable Polymer Everolimus- eluting Stent: A randomized, controlled, non-inferiority trial. J Am Coll Cardiol, 2013; 62: 181–190
39. Gao RL, Xu B, Lansky AJ et al. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus- eluting stent with a durable polymer everolimus-eluting stent: Clinical and angiographic follow-up of the TARGET I trial. EuroIntervention, 2013; 9: 75–83
40. Gao RL, Xu B, Yang Y et al. A prospective multicenter randomized trial of PROSTENT bioabsorbable polymer vs. FIREBIRD durable polymer sirolimus-eluting stent: 9-month angiographic and 12-month clinical results. J Am Coll Cardiol, 2010; 56: B55
41. Ge J. Sirolimus-eluting stent with biodegradable-polymer versus sirolius-eluting stent with durable polymer for the treatment of patients with de novo coronary artery lesions (EVOLUTION): A randomised non-inferiority trial. Presented at: EuroPCR 2012; May 17
42. Chevalier B, Serruys PWJC, Silber S et al. Nobori 1: Long term results: 3 years phase 1 and 2 and 4 years phase 1. EuroIntervention, 2010; 6 (Suppl. H): 39
43. Kimura T, Muramatsu T, Iwabuchi M et al. Three year follow up of a randomized comparison of NOBORI, Biolimus A9 eluting stent (BES) with CYPHER, Sirolimus eluting stent (SES) for coronary revascularization in Japanese population. J Am Coll Cardiol, 2012; 60: B182
44. Meredith IT, Verheye S, Dubois CL et al. Six-month IVUS and 12-month clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus- eluting stent. EuroIntervention, 2012; 8 (Suppl. N): 42
45. Abizaid A, Ormiston JA, Fajadet J et al. Two-year follow-up of the NEVO RES-ELUTION I (NEVO RES-I) trial: A randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberte paclitaxel-eluting stent in de novo native coronary artery lesions. EuroIntervention, 2013; 9: 721–729
46. Byrne RA, Kufner S, Tiroch K et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart, 2009; 95: 1489–1494
47. Meredith IT, Verheye S, Weissman NJ et al. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: A randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention, 2013; 9: 308–315
48. Puricel S, Oberhansli M, Guntern P et al. Long-term comparison of everolimus-eluting and biolimus-eluting stents. EuroIntervention, 2013; 9: 336–344
49. Palmerini T, Kirtane AJ, Serruys PW et al. Stent thrombosis with everolimus-eluting stents: Meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv, 2012; 5: 357–364
50. Kolandaivelu K, Swaminathan R, Gibson WJ et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation, 2011; 123: 1400–1409
51. Navarese E P, Koziński M, Pafundi T et al. Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology. Cardiol J, 2011; 18: 103–109.